# Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

> **NCT02547428** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 85 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity

## Interventions

- **DRUG:** CTN SR
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT02547428
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-03
- **Primary completion:** 2016-06-04
- **Final completion:** 2016-06-04
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2021-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02547428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02547428, "Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02547428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*